Rani Therapeutics Holdings IncNASDAQ:RANI
- LAST PRICE12.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots10.9800/ 1
- Ask / Lots21.0000/ 10
- Open / Previous Close0.0000 / 12.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RANI |
|---|---|---|
| 09:32 ET | 844 | 12.35 |
| 09:48 ET | 700 | 12.23 |
| 10:10 ET | 108 | 12.25 |
| 10:42 ET | 100 | 12.15 |
| 11:08 ET | 130 | 12.205 |
| 11:38 ET | 200 | 12.35 |
| 12:03 ET | 31693 | 12.75 |
| 12:05 ET | 298 | 12.68 |
| 12:14 ET | 5037 | 12.44 |
| 12:52 ET | 200 | 12.46 |
| 12:54 ET | 200 | 12.35 |
| 12:56 ET | 400 | 12.34 |
| 12:59 ET | 100 | 12.34 |
| 01:32 ET | 265 | 12.35 |
| 02:33 ET | 500 | 12.349 |
| 03:43 ET | 586 | 12.44 |
| 03:45 ET | 2363 | 12.39 |
| 03:52 ET | 1511 | 12 |
| 03:54 ET | 100 | 12.105 |
| 03:56 ET | 200 | 12.105 |
| 03:57 ET | 1300 | 12.39 |
| 03:59 ET | 6549 | 12 |
Today
BRIEF-Rani Therapeutics Enters Into $45 Mln Loan Agreement To Support Ranipill Platform Advancement, from 21 minutes ago by Thomson Reuters
21 minutes ago by Thomson ReutersRani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill(R) Platform Advancement and Clinical Pipeline Development, from 22 minutes ago by GlobeNewswire
22 minutes ago by GlobeNewswire
Aug 2, 2022
Rani Therapeutics Holdings Files $400 Million Mixed Shelf, from 3:11AM ET on Tuesday Aug 02, 2022 by MT Newswires
3:11AM ET on Tuesday Aug 02, 2022 by MT Newswires
Aug 1, 2022
BRIEF-Rani Therapeutics Files For Mixed Shelf Of Up To $400 Mln, from 5:52PM ET on Monday Aug 01, 2022 by Thomson Reuters
5:52PM ET on Monday Aug 01, 2022 by Thomson Reuters
Jul 27, 2022
--HC Wainwright Initiates Rani Therapeutics Holdings at Buy With $22 Price Target, from 7:38AM ET on Wednesday Jul 27, 2022 by MT Newswires
7:38AM ET on Wednesday Jul 27, 2022 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rani Therapeutics Holdings Inc | 589.9M | -66.7x | --- |
Dyne Therapeutics Inc | 590.9M | -3.7x | --- |
Janux Therapeutics Inc | 576.2M | -9.1x | --- |
Kinnate Biopharma Inc | 579.6M | -5.8x | --- |
Tricida Inc | 601.9M | -3.8x | --- |
Aerovate Therapeutics Inc | 610.3M | -18.9x | --- |
Company Information
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company’s technologies enable the development of orally administered biologics. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The Company manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.
Contact Information
- Headquarters
- 2051 Ringwood AvenueSAN JOSE, CA, United States 95131
- Phone
- 408-457-3700
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Mir Imran
- Chief Executive Officer, Director
- Talat Imran
- Chief Financial Officer
- Svai Sanford
- Chief Scientific Officer
- Mir Hashim
- General Counsel
- Eric Groen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $589.9M |
|---|---|
Revenue (TTM) | $2.0M |
Shares Outstanding | 49.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.18 |
Book Value | $0.97 |
P/E Ratio | -66.7x |
Price/Sales (TTM) | 300.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,104.59% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
